DCM
ATNM icon

DAFNA Capital Management’s Actinium Pharmaceuticals ATNM Stock Holding History

DAFNA Capital Management’s Portfolio ATNM Stock Details ATNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-11,100
Closed -$192K – 73
2017
Q3 		$192K Buy
+11,100
New +$244K 0.12% 66
2015
Q4 		– Sell
-3,000
Closed -$159K – 79
2015
Q3 		$159K Hold
3,000
– – 0.16% 75
2015
Q2 		$239K Hold
3,000
– – 0.2% 62
2015
Q1 		$222K Buy
+3,000
New +$357K 0.17% 61

Other funds holding ATNM

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
DADC
D.A. Davidson & Co Great Falls, Montana $16.5B AUM 19.94% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

DAFNA Capital Management's ATNM Position: Q4 2017 in Review

DAFNA Capital Management sold out of Actinium Pharmaceuticals (ATNM) in Q4 2017, closing a stake of 11,100 shares — an estimated $192K sold.

DAFNA Capital Management first reported a position in ATNM in Q1 2015 and held it in 4 quarters. The position peaked at $239K in Q2 2015. 28 funds tracked by Wall St. Rank hold ATNM as of Q4 2017.

  • DAFNA Capital Management reported no remaining Actinium Pharmaceuticals position as of Q4 2017 after selling out during the quarter.
  • DAFNA Capital Management sold 11,100 Actinium Pharmaceuticals shares in Q4 2017, an estimated $192K.
  • DAFNA Capital Management first reported a position in Actinium Pharmaceuticals in Q1 2015 and held it in 4 quarters.
  • DAFNA Capital Management's Actinium Pharmaceuticals position peaked at $239K in Q2 2015.
  • 28 funds tracked by Wall St. Rank held Actinium Pharmaceuticals as of Q4 2017.

Based on DAFNA Capital Management's 13F filing for Q4 2017, filed 14 Feb 2018.